Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02721433 |
| Title | 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA) |
| Acronym | REaCT-BTA |
| Recruitment | Completed |
| Gender | both |
| Phase | FDA approved |
| Variant Requirements | No |
| Sponsors | Ottawa Hospital Research Institute |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | CAN |